Identifying human cancers to target with BCL-2 inhibition
What is in the future for T-cell lymphoma?
An overview of the current treatment landscape of non-Hodgkin lymphoma
Is venetoclax appropriate for relapsed CLL patients?
BCL2 inhibition and CLL: the role of venetoclax